FDA allows less anticoagulation with On-X valve

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

The FDA expanded the labeling for a mechanical aortic valve by approving a lower International Normalized Ratio (INR) that is closer to an unmedicated range.

The FDA’s decision allows some patients implanted with On-X Aortic Heart Valves to reduce their anticoagulation therapy, which also may lower their risk of bleeding. Guidelines generally recommend patients treated with a mechanical valve maintain an INR of 2 to 3. The label change allows for an INR of 1.5 to 2 beginning three months after the implant.

The label expansion applies only to On-X mechanical aortic valves, which are made by Austin, Texas-based On-X Life Technologies.

Candace Stuart, Contributor

Related Content

How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
9 key takeaways from AHA 2024 in Chicago
Redo TAVR: The impact of implanting balloon-expandable valves in failed self-expanding valves
Edoxaban could limit blood clots, ‘make life easier’ for heart valve surgery patients

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."